You are here: Industry Insights > MyoKardia

News List

Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia prnewswire
January 11, 2021
Avidity Biosciences, Inc. announced pipeline updates for 2021 and a research collaboration with MyoKardia, Inc., a wholly-owned subsidiary of Bristol Myers Squibb.
BMS acquires biopharma firm MyoKardia for $13.1bn pharmaceutical-technology
November 19, 2020
Bristol Myers Squibb (BMS) has completed its acquisition of clinical-stage biopharma firm MyoKardia in an all-cash transaction for $13.1bn.
BMS to acquire biopharma firm MyoKardia for $13.1bn pharmaceutical-technology
October 10, 2020
Bristol Myers Squibb (BMS) has signed a definitive merger agreement to acquire clinical-stage biopharma firm MyoKardia, in a cash-based transaction valued at $13.1bn.
MyoKardia Doses First Patient in Danicamtiv Trial for Dilated Cardiomyopathy americanpharmaceuticalreview
September 15, 2020
MyoKardia announced the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere.
MyoKardia Receives Breakthrough Therapy Designation for Mavacamten americanpharmaceuticalreview
July 30, 2020
MyoKardia announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy.
Obstructive Hypertrophic Cardiomyopathy Study from MyoKardia Meets Primary, Secondary Endpoints americanpharmaceuticalreview
May 15, 2020
MyoKardia announced positive topline data from the company’s Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
Sanofi and MyoKardia end heart disease drug collaboration pharmatimes
January 04, 2019
Bringing an end to a four-year partnership, Sanofi has terminated its agreement with MyoKardia to jointly develop small-molecule therapeutics, targeting genetic mutations associated with certain heart diseases.
Sanofi offloads drug programmes to MyoKardia and Acer Therapeutics pharmaceutical-technology
January 04, 2019
Sanofi has returned worldwide rights to all programmes that were covered under a licence and collaboration agreement signed with biopharmaceutical company MyoKardia in 2014.
MyoKardia Sees Positive Results in Mid-Stage Heart Trial biospace
March 12, 2018
Shares of MyoKardia spiked in late trading Thursday after the company revealed positive results from a mid-stage obstructive hypertrophic cardiomyopathy trial.
MyoKardia transforms inherited heart disease symptoms in midstage trial fiercebiotech
August 08, 2017
An estimated 70,000 patients could potentially benefit from mavacamten if approved